Saratov JOURNAL of Medical and Scientific Research
Home

Comparative characteristics of melatonin content in lacrimal fluid and blood serum depending on the stage of senile cataract with age-related macular degeneration

Year: 2020, volume 16 Issue: №2 Pages: 673-678
Heading: Ophtalmology Article type: Original article
Authors: Khodzhaev N.S., Chuprov A.D., Smolyagin A.I., Kim S.M., Filippova Yu.V.
Organization: S. Fyodorov Eye Microsurgery Federal State Institution
Summary:

The purpose of the study is to evaluate factors affecting concentration of melatonin in the tear and blood serum in patients with a non-exudative form of age-related macular degeneration (AMD). Material and Methods. 140 patients (140 eyes) were examined, of which 52% were women, 48% were men. The following groups of patients were formed: 1) patients with non-exudative AMD and senile cataract who took melatonin; 2) patients with non-exudative AMD and senile cataract who did not take melatonin; 3) without AMD and cataract; 4) patients with non-exudative AMD, not requiring surgical treatment of cataract; 5) patients with neovascular (exudative) form of AMD (nAMD). The melatonin content was determined using immunosorbent assay. Results. The content of melatonin in all examined patients' serum ranged from 0.001 to 0.161 ng/ml, the highest median of melatonin values was observed in healthy individuals (0.125 ng/ml), and the lowest in patients with nAMD (0.021 ng/ml). The level of melatonin in the tear varies from 0.067 to 0.477 ng/ml, while its highest median was found in group 1 patients: 0.324 ng/ml. In group 2 and reference groups (without cataract with AMD and with nAMD), the melatonin content in the tear was significantly reduced (p <0.05) compared with the level in the group of healthy individuals. Conclusion. The content of melatonin in the blood serum and lacrimal fluid depends on the following factors: age, arterial hypertension, body mass index (BMI), insomnia, smoking, hair and eye color, night shifts. Using melatonin in the treatment of patients with AMD helps to increase the concentration of melatonin in tear.

Keywords: age-related macular degeneration, cataract, melatonin

Bibliography:
1. Prevention of Blindness and Visual Impairment: Priority Eye Diseases. Geneva: World Health Organization, 2004. URL: http://www.who.int/blindness/causes/priority/en (16 April 2020).
2. Pinna A, Zaccheddu F, Boscia F, et al. Homocysteine and risk of age-related macular degeneration: a systematic review and metaanalysis. Acta Ophthalmologica 2018; 96: 269-76.
3. Bahadorani S, Singer M. Recent advances in the management and understanding of macular degeneration. F1000Research2017;6:519.
4. Chatziralli I, Mitropoulos P, Parikakis E, et al. Risk Factors for Poor Quality of Life among Patients with Age-Related Macular Degeneration. Seminars in Ophthalmology 2016; 10: 1-9.
5. Tosini G, Baba K, Hwang CK, et al. Melatonin: An Underappreciated Player in Retinal Physiology and Pathophysiology. Experimental Eye Research 2012; 103: 82-9.
6. Ostrin LA. Ocular and systemic melatonin and the influence of light exposure. Clinical and Experimental Optometry 2019; 102 (2): 99-108.
7. Khorsand M, Akmali M, Sharzad S, et al. Melatonin Reduces Cataract Formation and Aldose Reductase Activity in Lenses of Streptozotocin-induced Diabetic Rat. Iranian Journal of Medical Sciences 2016; 41 (4): 305-13.
8. Blasiak J, Reiter RJ, Kaarniranta K. Melatonin in Retinal Physiology and Pathology: The Case of Age-Related Macular Degeneration. Oxidative Medicine and Cellular Longevity 2016; 2016:6819736.
9. Stefanova NA, Zhdankina AA, Fursova AZh, et al. Potential of melatonin for prevention of age-related macular degeneration: experimental study. Advances in Gerontology 2013; 26(1): 122-9.
10. Mendel VE, Mendel Ol. Melatonin: role in the body and therapeutic possibilities: Experience of using the drug Melaxen in Russian medical practice. Russian Medical Journal 2010; (6): 336.

AttachmentSize
2020_02-1_673-678.pdf355.68 KB
All articles of the authors: Chuprov A.D., Filippova Yu.V. , Khodzhaev N.S. , Kim S.M. , Smolyagin A.I.

No votes yet